**Effectiveness and Pharmacokinetics of Low-Dose All-trans Retinoic Acid (25 mg/m²) in Acute Promyelocytic Leukemia**

By Sylvie Castaigne, Philippe Lefebvre, Christine Chomienne, Etienne Suc, Francoise Rigal-Huguet, Claude Gardin, Alain Delmer, Eric Archimbaud, Hervé Tilly, Maud Janvier, Françoise Isnard, Philippe Travade, Luc Montfort, A. Delannoy, Marie Joséé Rapp, Bernard Christian, Marion Montastruc, Hans Weh, Pierre Fenaux, Hervé Dombret, Bernard Gourmel, and Laurent Degos

It has been shown that all-trans retinoic acid (ATRA) at doses of 45 to 100 mg/m²/d induces complete remission (CR) of acute promyelocytic leukemia (APL) by a differentiation process. To date, ATRA dose-ranging studies have not yet been evaluated. Thus, we initiated in May 1990 a multicenter study with ATRA at a lower dose of 25 mg/m²/d until CR. Thirty patients with APL were treated with ATRA, of whom 12 were previously untreated, 14 were in first relapse, and 4 had failed after conventional first induction chemotherapy. Twenty-four of 30 achieved CR, 3 failed, and 3 died before day 30. Median time to CR was 45 days. Hyperleucytosis (14 to 43 × 10⁹ white blood cells per liter) was observed in 9 patients between days 10 and 23. Clinical complications that may have been related to the retinoic acid syndrome were observed in 8 patients, of whom 3 died. Pharmacokinetics studies were performed in 5 patients. Peak plasma concentrations and mean area under the concentration-time curve were not lower than previous levels obtained under the 45 mg/m²² dose. Overall, our study shows that there is no difference in terms of therapeutic efficacy, triggering of hyperleucytosis, or retinoic acid syndrome and pharmacokinetic results with ATRA at 25 or 45 mg/m²².

© 1993 by The American Society of Hematology.

---

**PATIENTS AND METHODS**

From May 1990 to January 1992, 30 patients with an M3 leukemia from 15 different institutions in France, Belgium, and Germany were treated in their hospital of origin. Karyotypic analysis was available in 26 patients and showed the specific t(15;17) in 25. ATRA at a dose of 25 mg/m²²/d was administered in two oral doses until CR. Blood counts and coagulation tests were performed at least thrice weekly. Bone marrow examination was performed each month and/or at the time of response evaluation. Complete response was defined by the disappearance of APL blasts in the bone marrow and the normalization of blood counts for at least 2 months. Supportive care, prevention or treatment of the retinoic acid syndrome, and maintenance therapy were left to each center’s decision. Informed consent was obtained from all patients.

Patients. Thirty patients (13 male and 17 female) with a mean age of 56 years (range, 10 to 81) were treated. Twelve patients were treated for a newly diagnosed disease because of contraindication to conventional chemotherapy. There were 9 elderly patients (66 to 81 years), 2 obese patients with cardiac disease, and 1 human immunodeficiency virus (HIV)-positive patient. Fourteen patients were treated in first relapse after conventional chemotherapy. Four patients were treated after failure of conventional chemotherapy in-
duction. No patient presented with hyperleukocytosis before the onset of ATRA (white blood cell count [WBC], from 0.2 to 7.6 \( \times 10^9/L \); median, 1.6 \( \times 10^9/L \)). Coagulopathy (fibrinogen <200 mg/dL and/or elevation of fibrinogen degradation products or D dimers) was present in 8 patients.

Pharmacokinetics. Plasma pharmacokinetics were performed in 5 patients after the administration of a single oral dose of ATRA using a new method. Briefly, blood samples were collected in aluminum foil wrapped heparized tubes before ingestion, and again at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, and 24 hours, thereafter. After a solid phase extraction, the samples were analyzed by high performance liquid chromatography (HPLC) on a silica column in isocratic mode with UV detection (360 nm). In this method, the internal standard was the RO-10.1670 (isoretinoin). All samples were rigorously taken, stored, and manipulated in the dark or under subdued light. Model independent pharmacokinetic parameters were calculated for each patient. Elimination half-lives (t1/2B) were estimated by linear regression after log transformation of the concentrations. The area under the concentration-time curve (AUC) was calculated by the trapezoidal rule.

RESULTS

Induction therapy. Induction therapy results are shown in Table 1. Among the 12 patients treated for a newly diagnosed disease, 10 reached CR between days 30 and 90 (3 on day 30, 2 on day 45, 3 on day 60, and 2 on day 90). Two patients died: one on day 6 from cerebral hemorrhage (WBC, 1.6 \( \times 10^9/L \) at diagnosis, and 9 \( \times 10^9/L \) at the time of death), and one on day 17 with acute respiratory distress syndrome (ARDS; WBC, 0.9 \( \times 10^9/L \) at diagnosis and 14 \( \times 10^9/L \) on day 13). Among the 14 patients treated in first relapse, 10 reached CR (4 on day 30, 2 on day 45, 2 on day 60, and 2 on day 90). One patient had a transient partial response. t(15;17) was present at diagnosis in this patient. One patient died from ARDS on day 23 (WBC, 7 \( \times 10^9/L \) at the beginning of ATRA therapy and 34 \( \times 10^9/L \) on day 10). Two patients were considered as failures to respond. One patient failed to respond after 45 days of ATRA therapy and despite ATRA dose escalation to 45 mg/m² on day 20, 3 of 9 patients associated with clinical complications in 6 of 9. In 5 patients, hyperleukocytosis was not treated: 3 entered CR (maximum WBC count, 25 \( \times 10^9/L \) on day 23, 15 \( \times 10^9/L \) on day 20, 32 \( \times 10^9/L \) on day 10) and 2 died of ARDS (maximum WBC count, 14 \( \times 10^9/L \) on day 13; 34 \( \times 10^9/L \) on day 10). The other 4 patients received either chemotherapy or dexamethasone. Two elderly patients (aged 81 and 76 years) were treated with chemotherapy. The first patient received 6-mercaptopurine at 150 mg/d starting on day 20 (WBC

<table>
<thead>
<tr>
<th>Table 1. Results of Induction With ATRA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
</tr>
<tr>
<td>----</td>
</tr>
<tr>
<td>Newly diagnosed (N = 12)</td>
</tr>
<tr>
<td>First relapse (N = 14)</td>
</tr>
</tbody>
</table>

Date and cause of death: day 6, intracranial hemorrhage; day 17, cardiopulmonary failure (ATRA syndrome; WBC, 14 \( \times 10^9/L \) on day 13); day 23, ARDS (ATRA syndrome; WBC, 34 \( \times 10^9/L \) on day 10); day 50, ATRA syndrome and resistance. Abbreviation: PR, partial remission.

The 4 patients treated with ATRA therapy after failure of conventional chemotherapy entered CR on days 15 to 30 (1 on day 15, 3 on day 30).

Maintenance treatment and response durations. Results are indicated in Table 2. One elderly patient (80 years old) did not receive any maintenance therapy because of psychologic reasons (severe depression) and died 2 months later from a cause unrelated to her hematologic disease. The result of maintenance treatment was not known for 1 patient treated with ATRA after failure of induction.

Five patients received a consolidation course with daunorubicin (45 mg/m²/d) for 3 days and Ara-C (200 mg/m²/d) for 7 days, followed by maintenance therapy with 6-mercaptopurine and methotrexate or low-dose Ara-C. These patients are in continuous CR on month 6 to 14. Eleven patients received three monthly mild consolidation courses as outpatients with anthracyclins or amsacrine on day 1 and cytosine arabinoside by subcutaneous injections for 5 days. Eight of these patients have relapsed (median duration of CR, 10 months). Three patients received an autologous bone marrow transplant: 1 died of the procedure, 1 has relapsed on month 19, and 1 is alive in CR after 14 months. One patient received low-dose Ara-C and continues to be in CR on month 8. One patient continued ATRA alone and relapsed on month 3. One patient was treated with consolidation courses as an outpatient and then received an allogenic bone marrow transplantation with an unrelated donor and is alive in CR 6 months after.

One newly diagnosed patient who achieved CR with ATRA therapy and received mild consolidation courses as an outpatient and then maintenance treatment with 6-mercaptopurine and methotrexate relapsed 2 years later. He was treated again with ATRA therapy and remission was easily obtained.

Clinical and biologic side effects. Clinical complications occurred in 11 patients: cerebral hemorrhage on day 6, ARDS in 2 patients, isolated fever of unknown origin in 1 patient or associated with pleural effusions in 2 patients, pulmonary infiltrates in 1, cutaneous erythema in 1, arthralgias in 1, and fever concomitant to clinical evidence of infections in 2 patients. Four patients died: 1 of cerebral hemorrhage on day 6, 2 with ARDS on days 17 and 23, and 1 with ATRA resistance on day 50. Overall, 8 patients experienced some of the clinical symptoms that may be related to the retinoic acid syndrome. Complications related to ATRA therapy may have been the cause of death in 3 patients.

Hyperleukocytosis (WBC, > 10 \( \times 10^9/L \)) was observed in 9 patients who achieved a maximal WBC count (14 to 43 \( \times 10^9/L \) between days 10 and 23. Hyperleukocytosis was associated with clinical complications in 6 of 9. In 5 patients, hyperleukocytosis was not treated: 3 entered CR (maximum WBC count, 25 \( \times 10^9/L \) on day 23, 15 \( \times 10^9/L \) on day 20, 32 \( \times 10^9/L \) on day 10) and 2 died of ARDS (maximum WBC count, 14 \( \times 10^9/L \) on day 13; 34 \( \times 10^9/L \) on day 10). The other 4 patients received either chemotherapy or dexamethasone. Two elderly patients (aged 81 and 76 years) were treated with chemotherapy. The first patient received 6-mercaptopurine at 150 mg/d starting on day 20 (WBC
count, 32 × 10⁹/L; the second one received VP16 at 175 mg for 1 day and cytosine arabinoside at 180 mg/d for 5 days, starting on day 23 (WBC count, 16 × 10⁹/L). Both patients entered CR. In 2 patients (maximum WBC count, 43 × 10⁹/L on day 10 and 20 × 10⁹/L on day 15), ATRA therapy was stopped for 1 to 2 weeks and dexamethazone was introduced; both reached CR.

Extra hematologic side effects such as headache and dryness of mucous were considered negligible.

**Pharmacokinetics.** ATRA plasma pharmacokinetic studies were performed in 5 patients. The time to peak plasma concentrations was 60 to 240 minutes (mean, 132 minutes). The peak plasma concentration varied from 0.22 to 4.34 μg/mL (mean, 1.63 μg/mL), and mean AUC was 733 ngH/mL.

**DISCUSSION**

The data presented here show that ATRA at a dose of 25 mg/m²/d is quite effective in inducing CR in M3 patients as 24 of 30 patients reached CR.

Among the 6 patients who did not reach CR, 3 died before evaluation: 1 newly diagnosed patient died early from cerebral hemorrhage. 2 patients (one newly-diagnosed and one first relapsing) died at week 3 of therapy of an ARDS concomitant with hyperleukocytosis. One patient treated in first relapse had a transient response. Two patients treated both in first relapse may be considered refractory to ATRA. However, these 2 patients had the specific t15;17 on karyotypic analysis. Our results are not different from those observed in previous studies with ATRA at a dose of 45 mg/m².d. In our first study, we observed among 22 patients 3 early deaths, 4 transient responses, 1 resistance, and 14 CR.

Median time to CR (45 days) is also within the range observed with a higher dose.

Hyperleukocytosis (WBC > 10 × 10⁹/L) was observed in one-third of the patients. Again, this frequency is not different from previous studies using ATRA at a dose of 45 mg/m²/d. In our first study among 15 leukopenic patients at the beginning of ATRA therapy, 4 presented an hyperleukocytosis greater than 10 × 10⁹/L. Frankel et al.¹² reported 14 of 35 patients with hyperleukocytosis greater than 20 × 10⁹/L.

Fourteen patients experienced clinical or biologic symptoms under ATRA. In 8 of them, clinical symptoms may be related to the retinoic acid syndrome and in 3 patients ATRA side effects may have been the cause of death. On the contrary, ATRA was extremely well tolerated without any biologic or clinical side effects in 16 patients (4 of 12 in first induction, 9 of 14 relapsing, and 3 of 4 after induction chemotherapy failure). As in our previous study, we found a relationship between hyperleukocytosis and the occurrence of clinical side effects (Table 3). But, as pointed out in the study of Frankel et al.¹² this relationship is not absolute and some patients may experience well-tolerated hyperleukocytosis, whereas severe retinoic acid syndrome may occur concomitantly with a moderate increase in leukocytes. However, once established, retinoic acid syndrome, especially with pulmonary complications, is difficult to manage. For this reason, in a European multicentric prospective trial using ATRA as treatment for newly diagnosed patients, it was decided to treat patients who developed hyperleukocytosis with full-dose chemotherapy.¹³ In the study presented here, which includes patients with contraindication to conventional chemotherapy, management of hyperleukocytosis and/or retinoic acid syndrome was decided locally. Because of the small number of patients studied, it is difficult to conclude in favor of either chemotherapy or dexamethazone treatment. Moreover, as previously reported, in 3 cases, hyperleukocytosis without clinical complications did not require treatment and receded spontaneously after day 21.

**Table 2. Duration of CR**

| Table 3. Correlation Between Hyperleukocytosis and Clinical Complications |
|-----------------------------|-----------------------------|
| Clinical Complications | + | - |
| Hyperleukocytosis | 6 | 3 |
| - | 5 | 16 |
| *P < .05* |

Thus, in our experience, there is no difference in terms of therapeutic efficacy, triggering of hyperleukocytosis, or retinoic acid syndrome with ATRA at 25 or 45 mg/m²/d. This is not surprising when we refer to the pharmacokinetics results. Peak plasma concentration varied from 0.22 to 4.34 μg/mL. In our previous study with 45 mg/m², peak plasma concentrations were in the same range (0.03 to 2.5 μg/mL; mean, 0.4 μg/mL), and the mean AUC level was 733 ngH/mL.
tance to ATRA therapy is another main side effect of this treatment. Mechanisms of resistance are not clearly understood. It has been shown that chronic oral administration of ATRA resulted in a progressive decrease in peak plasma concentrations and in AUC values, with an increase of urinary elimination of its metabolite suggesting an increased catabolism of the drug. Increased catabolism may be due to induction of cytochrome P450-like enzyme systems and/or to an increase of cytoplasmic retinoic acid binding proteins in normal tissues that could clear the drug from plasma. In this study, only 1 patient, who achieved CR with ATRA as a first induction, was treated again with ATRA when relapse occurred 2 years later. A second remission was easily obtained with ATRA. This single observation does not permit us to conclude that absence of acquired resistance was caused by reduced ATRA doses used during the first treatment. An alternative explanation may also be the long withdrawal (2 years) from ATRA between two treatments. If the acquired resistance is generally reported, one study mentioned that a second reinduction remission with ATRA was possible in patients treated for a short period with this drug.

ATRA is a novel and very promising therapy in APL. Recent studies have shown that ATRA followed by or combined with conventional chemotherapy may be more beneficial for patients than chemotherapy alone. However, a subset of APL patients, elderly or relapsing, are not candidates for conventional chemotherapy. Further studies about the appropriate doses or length of ATRA therapy are needed to optimize this therapy, both as an induction and maintenance treatment, in de novo and relapsing APL patients. We recently initiated a study with ATRA 15 mg/m²/day until CR in elderly or first relapsing patients. Preliminary results show an equal efficacy and tolerance.

REFERENCES

Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia

S Castaigne, P Lefebvre, C Chomienne, E Suc, F Rigel-Huguet, C Gardin, A Delmer, E Archimbaud, H Tilly and M Janvier